Page last updated: 2024-08-21

2,2-dimethylbutyric acid and HbS Disease

2,2-dimethylbutyric acid has been researched along with HbS Disease in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abboud, MR; Ataga, KI; Buchanan, GR; El-Beshlawy, A; Ghalie, RG; Inati, A; Kutlar, A; Perrine, SP; Reid, ME; Smith, H; Taher, AT1
Abboud, MR; El Beshlawy, A; Ghalie, RG; Haynes, J; Inati, A; Kutlar, A; Manwani, D; Reid, ME; Sharon, B; Smith, W; Taher, AT; Ward, R1
Cohen, H; Ghalie, R; Knapp, E; Kutlar, A; Manwani, D1
Ataga, K; Berenson, R; Blair-Britt, L; Glass, J; Keefer, JR; Kutlar, A; Labotka, R; Neumayr, L; Perrine, SP; Reid, M; Vichinsky, EP; Wargin, WA1

Trials

3 trial(s) available for 2,2-dimethylbutyric acid and HbS Disease

ArticleYear
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
    American journal of hematology, 2013, Volume: 88, Issue:11

    Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Butyrates; Child; Cohort Studies; Dose-Response Relationship, Drug; Female; Fetal Hemoglobin; Gastritis; Hematinics; Heterozygote; Humans; Hydroxyurea; Incidence; Male; Middle Aged; Patient Dropouts; Promoter Regions, Genetic; Sickle Cell Trait; Up-Regulation; Young Adult

2013
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
    American journal of hematology, 2014, Volume: 89, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Butyrates; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fetal Hemoglobin; Humans; Male; Middle Aged; Placebos; Young Adult

2014
A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.
    American journal of hematology, 2012, Volume: 87, Issue:11

    Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Biological Availability; Butyrates; Chromatography, High Pressure Liquid; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erythrocytes; Female; Fetal Hemoglobin; Hematinics; Humans; Male; Middle Aged; Young Adult

2012

Other Studies

1 other study(ies) available for 2,2-dimethylbutyric acid and HbS Disease

ArticleYear
Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents.
    American journal of hematology, 2016, Volume: 91, Issue:3

    Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Biomarkers; Butyrates; Child; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Fetal Hemoglobin; Humans; Middle Aged; Time Factors; Young Adult

2016